Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial

for the MEASURE 1 study group

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences